Oncotarget

Research Papers:

Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples

Bang-Fen Zhou, Jin-Huan Wei, Zhen-Hua Chen, Pei Dong, Ying-Rong Lai, Yong Fang, Hui-Ming Jiang, Jun Lu, Fang-Jian Zhou, Dan Xie _, Jun-Hang Luo and Wei Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:41703-41714. https://doi.org/10.18632/oncotarget.9406

Metrics: PDF 904 views  |   HTML 1113 views  |   ?  


Abstract

Bang-Fen Zhou1,2,*, Jin-Huan Wei3,*, Zhen-Hua Chen3,*, Pei Dong4, Ying-Rong Lai5, Yong Fang1, Hui-Ming Jiang1,6, Jun Lu1, Fang-Jian Zhou4, Dan Xie1, Jun-Hang Luo3, Wei Chen3

1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

2Department of Urology, Hainan Provincal Nongken General Hospital, Haikou, Hainan, China

3Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

4Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

5Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

6Department of Urology, Meizhou People’s Hospital, Guangdong, China

*These authors have contributed equally to this work

Correspondence to:

Dan Xie, email: xied@mail.sysu.edu.cn

Jun-Hang Luo, email: luojunh@mail.sysu.edu.cn

Wei Chen, email: chenw3@mail.sysu.edu.cn

Keywords: bladder cancer, AIB1, EIF5A2, diagnostic model, urine biomarkers

Received: October 23, 2015    Accepted: March 28, 2016    Published: May 17, 2016

ABSTRACT

We previously demonstrated that amplified in breast cancer 1 (AIB1) and eukaryotic initiation factor 2 (EIF5A2) overexpression was an independent predictor of poor clinical outcomes for patients with bladder cancer (BCa). In this study, we evaluated the usefulness of AIB1 and EIF5A2 alone and in combination with nuclear matrix protein 22 (NMP22) as noninvasive diagnostic tests for BCa. Using urine samples from 135 patients (training set, controls [n = 50] and BCa [n = 85]), we detected the AIB1, EIF5A2, and NMP22 concentrations using enzyme-linked immunosorbent assay. We applied multivariate logistic regression analysis to build a model based on the three biomarkers for BCa diagnosis. The diagnostic accuracy of the three biomarkers and the model were assessed and compared by the area under the curve (AUC) of the receiver operating characteristic. We validated the diagnostic accuracy of these biomarkers and the model in an independent validation cohort of 210 patients. In the training set, urinary concentrations of AIB1, EIF5A2, and NMP22 were significantly elevated in BCa. The AUCs of AIB1, EIF5A2, NMP22, and the model were 0.846, 0.761, 0.794, and 0.919, respectively. The model had the highest diagnostic accuracy when compared with AIB1, EIF5A2, or NMP22 (p < 0.05 for all). The model had 92% sensitivity and 92% specificity. We obtained similar results in the independent validation cohort. AIB1 and EIF5A2 show promise for the noninvasive detection of BCa. The model based on AIB1, EIF5A2, and NMP22 outperformed each of the three individual biomarkers for detecting BCa.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9406